Interleukin-6 induces cellular insulin resistance in hepatocytes.

Interleukin (IL)-6 is one of several proinflammatory cytokines that have been associated with insulin resistance and type 2 diabetes. A two- to threefold elevation of circulating IL-6 has been observed in these conditions. Nonetheless, little evidence supports a direct role for IL-6 in mediating insulin resistance. Here, we present data that IL-6 can inhibit insulin receptor (IR) signal transduction and insulin action in both primary mouse hepatocytes and the human hepatocarcinoma cell line, HepG2. This inhibition depends on duration of IL-6 exposure, with a maximum effect at 1-1.5 h of pretreatment with IL-6 in both HepG2 cells and primary hepatocytes. The IL-6 effect is characterized by a decreased tyrosine phosphorylation of IR substrate (IRS)-1 and decreased association of the p85 subunit of phosphatidylinositol 3-kinase with IRS-1 in response to physiologic insulin levels. In addition, insulin-dependent activation of Akt, important in mediating insulin's downstream metabolic actions, is markedly inhibited by IL-6 treatment. Finally, a 1.5-h preincubation of primary hepatocytes with IL-6 inhibits insulin-induced glycogen synthesis by 75%. These data suggest that IL-6 plays a direct role in insulin resistance at the cellular level in both primary hepatocytes and HepG2 cell lines and may contribute to insulin resistance and type 2 diabetes.

[1]  L Wood,et al.  Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. , 2001, American journal of physiology. Endocrinology and metabolism.

[2]  B. Spiegelman,et al.  Tumor necrosis factor alpha inhibits signaling from the insulin receptor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[3]  A. Steensberg,et al.  Muscle‐derived interleukin‐6: possible biological effects , 2001, The Journal of physiology.

[4]  S. Ito,et al.  Interleukin 1β and interleukin 6, but not tumor necrosis factor α, inhibit insulin‐stimulated glycogen synthesis in rat hepatocytes , 1998 .

[5]  B. Posner,et al.  Compartmentalization and insulin-induced translocations of insulin receptor substrates, phosphatidylinositol 3-kinase, and protein kinase B in rat liver. , 2000, Endocrinology.

[6]  G. Shulman,et al.  Prevention of fat-induced insulin resistance by salicylate. , 2001, The Journal of clinical investigation.

[7]  A. Marette,et al.  Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle , 2001, Nature Medicine.

[8]  E. Van Obberghen,et al.  SOCS-3 Is an Insulin-induced Negative Regulator of Insulin Signaling* , 2000, The Journal of Biological Chemistry.

[9]  D. Walsh,et al.  The cancer anorexia-cachexia syndrome. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Van Obberghen,et al.  SOCS-3 Inhibits Insulin Signaling and Is Up-regulated in Response to Tumor Necrosis Factor-α in the Adipose Tissue of Obese Mice* , 2001, The Journal of Biological Chemistry.

[11]  D. Hilton,et al.  SOCS: physiological suppressors of cytokine signaling. , 2000, Journal of cell science.

[12]  J. Kolls,et al.  An in Vivo Model for Elucidation of the Mechanism of Tumor Necrosis Factor-α (TNF-α)-Induced Insulin Resistance: Evidence for Differential Regulation of Insulin Signaling by TNF-α. , 1998, Endocrinology.

[13]  H. Sekihara,et al.  Augmented Production of Tumor Necrosis Factor-α in Obese Mice , 1995 .

[14]  M. White,et al.  Phosphorylation of Ser307 in Insulin Receptor Substrate-1 Blocks Interactions with the Insulin Receptor and Inhibits Insulin Action* , 2002, The Journal of Biological Chemistry.

[15]  Warren S. Alexander,et al.  A family of cytokine-inducible inhibitors of signalling , 1997, Nature.

[16]  S. Akira,et al.  Signal Transducer and Activator of Transcription (Stat)-Induced Stat Inhibitor 1 (Ssi-1)/Suppressor of Cytokine Signaling 1 (Socs1) Inhibits Insulin Signal Transduction Pathway through Modulating Insulin Receptor Substrate 1 (Irs-1) Phosphorylation , 2001, The Journal of experimental medicine.

[17]  J. Peschon,et al.  Analysis of liver regeneration in mice lacking type 1 or type 2 tumor necrosis factor receptor: Requirement for type 1 but not type 2 receptor , 1998 .

[18]  H. Sauerwein,et al.  Interleukin-6 enhances glucose transport in 3T3-L1 adipocytes. , 1996, Biochemical and biophysical research communications.

[19]  T. Bártfai,et al.  IL-6 is essential in TNF-alpha-induced fever. , 1998, The American journal of physiology.

[20]  D. Papanicolaou,et al.  Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. , 1997, The Journal of clinical endocrinology and metabolism.

[21]  S. Cameron,et al.  Suppressors of Cytokine Signaling-1 and -6 Associate with and Inhibit the Insulin Receptor , 2001, The Journal of Biological Chemistry.

[22]  U. K. Laemmli,et al.  Cleavage of structural proteins during , 1970 .

[23]  M. Papa,et al.  Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. , 1993, The Journal of biological chemistry.

[24]  J. Pickup,et al.  Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. , 2000, Life sciences.

[25]  W. Ricart,et al.  Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/phenotype to thriftiness , 1999, Diabetologia.

[26]  G. Shulman,et al.  Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. , 2001, The Journal of clinical investigation.

[27]  A. Marette,et al.  Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. , 2001, The Journal of biological chemistry.

[28]  Michael Karin,et al.  Reversal of Obesity- and Diet-Induced Insulin Resistance with Salicylates or Targeted Disruption of Ikkβ , 2001, Science.

[29]  Margaret S. Wu,et al.  Targeted Disruption of the Tumor Necrosis Factor-α Gene: Metabolic Consequences in Obese and Nonobese Mice , 1997, Diabetes.

[30]  J. Manson,et al.  C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.

[31]  J. Soria,et al.  Factors influencing the effect of the soluble IL-6 receptor on IL-6 responses in HepG2 hepatocytes. , 2000, Cytokine.

[32]  B. Spiegelman,et al.  Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. , 1994, The Journal of clinical investigation.

[33]  J. Ulbrecht,et al.  Muscle damage impairs insulin stimulation of IRS-1, PI 3-kinase, and Akt-kinase in human skeletal muscle. , 2000, American journal of physiology. Endocrinology and metabolism.

[34]  J. Kolls,et al.  Tumor Necrosis Factor-Induces Hepatic Insulin Resistance in Obese Zucker ( fa / fa ) Rats via Interaction of Leukocyte Antigen-Related Tyrosine Phosphatase With Focal Adhesion Kinase , 2000 .

[35]  B. Spiegelman,et al.  IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-α- and Obesity-Induced Insulin Resistance , 1996, Science.

[36]  W. Ricart,et al.  Interleukin-6 gene polymorphism and insulin sensitivity. , 2000, Diabetes.

[37]  K. Uysal,et al.  Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. , 1997, Nature.

[38]  H. Sekihara,et al.  Augmented production of tumor necrosis factor-alpha in obese mice. , 1995, Clinical immunology and immunopathology.

[39]  C. Hardin.  Making sense of oxygen sensing , 2001, The Journal of physiology.

[40]  J S Yudkin,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Subcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor-�, in Vivo* , 2022 .

[41]  K. Claffey,et al.  TNF-α impairs insulin signaling and insulin stimulation of glucose uptake in C2C12muscle cells. , 1999, American journal of physiology. Endocrinology and metabolism.

[42]  T. Sasaoka,et al.  Growth hormone induces cellular insulin resistance by uncoupling phosphatidylinositol 3-kinase and its downstream signals in 3T3-L1 adipocytes. , 2001, Diabetes.

[43]  B. Evers,et al.  Cytokine-mediated differential induction of hepatic activator protein-1 genes. , 1998, Surgery.

[44]  K. Uysal,et al.  Protection from obesity-induced insulin resistance in mice lacking TNF-α function , 1997, Nature.

[45]  T. Shiba,et al.  Hyperglycaemia due to insulin resistance caused by interferon‐γ , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[46]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[47]  P. Heinrich,et al.  Expression of suppressors of cytokine signaling during liver regeneration. , 2001, The Journal of clinical investigation.

[48]  J. Kolls,et al.  Tumor necrosis factor-alpha induces hepatic insulin resistance in obese Zucker (fa/fa) rats via interaction of leukocyte antigen-related tyrosine phosphatase with focal adhesion kinase. , 2000, Diabetes.

[49]  E. Van Obberghen,et al.  Serine/threonine phosphorylation of insulin receptor substrate 1 modulates insulin receptor signaling. , 1994, The Journal of biological chemistry.